Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Scientific Data
|
May 30, 2026
Quantitative transcriptome and proteome maps of classical nonclinical species
Elias Oziolor, Liang Xue, Dennis Pelletier, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 9, 2012
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function
Brooke H Miller, Zane Zeier, Li Xi, et al.
Cancer Immunology, Immunotherapy : CII
|
May 3, 2025
Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury
Changhua Ji, Steven Kumpf, Jessie Qian, et al.
Molecular Psychiatry
|
October 16, 2013
A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing
X Hu, B Zhang, W Liu, et al.
Journal of Parkinson'S Disease
|
February 3, 2020
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts
Shalini Padmanabhan, Thomas A Lanz, Donal Gorman, et al.
Molecular Therapy. Methods & Clinical Development
|
November 11, 2024
Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients
Michael R Emami, Mark A Brimble, Alejandro Espinoza, et al.
Journal of Neurology
|
July 15, 2025
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern
Thomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Chemistry & Biology
|
December 17, 2015
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities
Eugene L Piatnitski Chekler, Jessica A Pellegrino, Thomas A Lanz, et al.
Journal of Neurology
|
October 29, 2025
Correction: Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern
Thomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Journal of Molecular Biology
|
December 27, 2011
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease
Sherry L La Porte, Sangeetha Subbarao Bollini, Thomas A Lanz, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Scientific Data
|
May 30, 2026
Quantitative transcriptome and proteome maps of classical nonclinical species
Elias Oziolor, Liang Xue, Dennis Pelletier, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 9, 2012
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function
Brooke H Miller, Zane Zeier, Li Xi, et al.
Cancer Immunology, Immunotherapy : CII
|
May 3, 2025
Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury
Changhua Ji, Steven Kumpf, Jessie Qian, et al.
Molecular Psychiatry
|
October 16, 2013
A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing
X Hu, B Zhang, W Liu, et al.
Journal of Parkinson'S Disease
|
February 3, 2020
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts
Shalini Padmanabhan, Thomas A Lanz, Donal Gorman, et al.
Molecular Therapy. Methods & Clinical Development
|
November 11, 2024
Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients
Michael R Emami, Mark A Brimble, Alejandro Espinoza, et al.
Journal of Neurology
|
July 15, 2025
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern
Thomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Chemistry & Biology
|
December 17, 2015
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities
Eugene L Piatnitski Chekler, Jessica A Pellegrino, Thomas A Lanz, et al.
Journal of Neurology
|
October 29, 2025
Correction: Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern
Thomas A Lanz, Klemens Ruprecht, Christopher J Somps, et al.
Journal of Molecular Biology
|
December 27, 2011
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease
Sherry L La Porte, Sangeetha Subbarao Bollini, Thomas A Lanz, et al.
Page
of 8